MiR-182 promotes glioma progression by targeting FBXW7

Liu, Shiming; Liu, Hanbo; Deng, Min; Wang, Haowen

doi:10.1016/j.jns.2020.116689

Cited by 15 publications

(11 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A meta-analysis done by Li et al showed the prognostic potential of microRNA 21 in glioma patients. MicroRNA 182 Melanoma, papillary thyroid, and ovarian Cancer It reduces the function of FBXW7, which acts to induce apoptosis in cells via ubiquitination mediated degradation 40,41 MicroRNA 10b Breast, hepatic, pancreatic, and esophageal cancer…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Potential of MicroRNAs in Glioma Patients: A Meta-Analysis

Laghari

Suchal

Avani

et al. 2022

ASJO

View full text Add to dashboard Cite

Introduction MicroRNAs are a noncoding RNA involved in affecting several transcription and translation pathways. Their use has been discussed as potential predictors of several tumors. Their use as potential biomarker in glioma patients is still controversial. The purpose of this meta-analysis is to explore the possible role of such microRNAs in glioma patients. Methods After an extensive literature search done on PubMed and Embase, 20 studies were chosen for our analyses with the 9 discussing 11 tumor promoting microRNAs and 11 studies discussing 11 tumor suppressing microRNAs. The data needed was extracted from these studies including the hazard ratio that was used as the effect size for the purpose of our analysis. The needed analysis was performed using Stata and Excel. Results The pooled hazard ratio for our analysis with patients having a lower microRNA expression for tumor promoting microRNAs came to be 2.63 (p < 0.001), while the hazard ratio for patients with higher expression of tumor promoting microRNA was 2.47 (p < 0.001) with both results being statistically significant. However, as significant heterogeneity was observed a random effect model for analysis was used. Subgroup analysis was further performed using grade, cutoff value (mean or median), sample type (Serum or Blood), and Karnofsky performance score, all of them showing a high hazard ratio. Conclusion Our results showed that both tumor inhibitory and promoting microRNA can be used as prognostic tool in glioma patients with a poorer prognosis associated with a lower expression in tumor suppressive and higher expression in tumor promoting microRNA, respectively. However, to support this, future studies on a much larger scale would be needed.

show abstract

Section: Discussionmentioning

confidence: 99%

“…It reduces the function of FBXW7, which acts to induce apoptosis in cells via ubiquitination mediated degradation 40 41…”

Section: Discussionmentioning

confidence: 99%

Prognostic Potential of MicroRNAs in Glioma Patients: A Meta-Analysis

Laghari

Suchal

Avani

et al. 2022

ASJO

View full text Add to dashboard Cite

show abstract

“…SREBP2 induces miR-96 and miR-182 that directly suppress its negative regulator FBXW7, which results in a positive feed forward loop [ 67 ]. miR-182 has also been associated with the progression of glioma and breast cancers by directly targeting FBXW7 [ 68 , 69 ]; again highlighting the broad role indiviudal miRNAs play in regulating FBXW7 across various cancers. High levels of miR-32 expression downregulate FBXW7, promote cell proliferation, migration and suppress apoptosis in breast cancer [ 47 ].…”

Section: Introductionmentioning

confidence: 99%

Clinical significance of FBXW7 loss of function in human cancers

Fan

Bellon

et al. 2022

Mol Cancer

View full text Add to dashboard Cite

FBXW7 (F-Box and WD Repeat Domain Containing 7) (also referred to as FBW7 or hCDC4) is a component of the Skp1-Cdc53 / Cullin-F-box-protein complex (SCF/β-TrCP). As a member of the F-box protein family, FBXW7 serves a role in phosphorylation-dependent ubiquitination and proteasome degradation of oncoproteins that play critical role(s) in oncogenesis. FBXW7 affects many regulatory functions involved in cell survival, cell proliferation, tumor invasion, DNA damage repair, genomic instability and telomere biology. This thorough review of current literature details how FBXW7 expression and functions are regulated through multiple mechanisms and how that ultimately drives tumorigenesis in a wide array of cell types. The clinical significance of FBXW7 is highlighted by the fact that FBXW7 is frequently inactivated in human lung, colon, and hematopoietic cancers. The loss of FBXW7 can serve as an independent prognostic marker and is significantly correlated with the resistance of tumor cells to chemotherapeutic agents and poorer disease outcomes. Recent evidence shows that genetic mutation of FBXW7 differentially affects the degradation of specific cellular targets resulting in a distinct and specific pattern of activation/inactivation of cell signaling pathways. The clinical significance of FBXW7 mutations in the context of tumor development, progression, and resistance to therapies as well as opportunities for targeted therapies is discussed.

show abstract

“…Apart from involvement in cancer, downregulation of FBXW7 by miR-322 demonstrates a possible curing method to protect myocardium from ischemia/reperfusion injury. Collectively, there are still other miRNAs, such as miR129 (61), miR-92a-3p (62), miR182 (63), miR-27a-3p (64,65), miR-212/132 (66), miR-223-3p (67), miR-103a-3p (68), miR-25 (69), miR−25−3p (70), miR-144 (71), miR-101 (72), miR-188-5p (73), and miR-500a-3p (74), functioning discrepantly to mediate different cell phenotypes but via the identical mechanism of targeting FBXW7.…”

Section: Microrna Regulation Of Fbxw7mentioning

confidence: 99%

Recent Insight on Regulations of FBXW7 and Its Role in Immunotherapy

Xing

Zhang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

SCFFBXW7 E3 ubiquitin ligase complex is a crucial enzyme of the ubiquitin proteasome system that participates in variant activities of cell process, and its component FBXW7 (F-box and WD repeat domain–containing 7) is responsible for recognizing and binding to substrates. The expression of FBXW7 is controlled by multiple pathways at different levels. FBXW7 facilitates the maturity and function maintenance of immune cells via functioning as a mediator of ubiquitination-dependent degradation of substrate proteins. FBXW7 deficiency or mutation results in the growth disturbance and dysfunction of immune cell, leads to the resistance against immunotherapy, and participates in multiple illnesses. It is likely that FBXW7 coordinating with its regulators and substrates could offer potential targets to improve the sensitivity and effects of immunotherapy. Here, we review the mechanisms of the regulation on FBXW7 and its tumor suppression role in immune filed among various diseases (mostly cancers) to explore novel immune targets and treatments.

show abstract

MiR-182 promotes glioma progression by targeting FBXW7

Cited by 15 publications

References 19 publications

Prognostic Potential of MicroRNAs in Glioma Patients: A Meta-Analysis

Prognostic Potential of MicroRNAs in Glioma Patients: A Meta-Analysis

Clinical significance of FBXW7 loss of function in human cancers

Recent Insight on Regulations of FBXW7 and Its Role in Immunotherapy

Contact Info

Product

Resources

About